Lautenschläger C, Schmidt C, Fischer D, Stallmach A (2014) Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 71:58–76

PubMed  Article  CAS  Google Scholar 

Colombel J-F, D’haens G, Lee W-J, Petersson J, (2020) Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. Journal of Crohn’s and Colitis. 14:254–66

Palmela C, Torres J, Cravo M (2015) New trends in inflammatory bowel disease. GE Port J Gastroenterol 22:103–111

PubMed  PubMed Central  Article  Google Scholar 

Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:329–342

CAS  PubMed  Article  Google Scholar 

Belali N, Wathoni N, Muchtaridi M (2019) Advances in orally targeted drug delivery to colon. J Adv Pharm Technol Res 10:100–106

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S et al (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology 119:1461–1472

CAS  PubMed  Article  Google Scholar 

Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA et al (2014) Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146:210-221.e13

CAS  PubMed  Article  Google Scholar 

Tang K-Y, Lickliter J, Huang Z-H, Xian Z-S, Chen H-Y, Huang C et al (2019) Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects Cellular & Molecular Immunology. Nature Publishing Group 16:473–82

CAS  Google Scholar 

Doll F, Schwager K, Hemmerle T, Neri D (2013) Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther 15:R138

PubMed  PubMed Central  Article  CAS  Google Scholar 

Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak J-N et al (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405–2413

CAS  PubMed  Article  Google Scholar 

Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D et al (2009) Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 11:R142

PubMed  PubMed Central  Article  CAS  Google Scholar 

Bootz F, Ziffels B, Neri D. Antibody-based targeted delivery of interleukin promotes rapid clinical recovery in mice with DSS-induced colitis: inflammatory bowel diseases.22:2098–105

Petrey AC, de la Motte CA (2017) The extracellular matrix in IBD: a dynamic mediator of inflammation. Curr Opin Gastroenterol 33:234–238

CAS  PubMed  PubMed Central  Article  Google Scholar 

Riedl S, Tandara A, Reinshagen M, Hinz U, Faissner A, Bodenmüller H et al (2001) Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 16:285–291

CAS  PubMed  Article  Google Scholar 

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE et al (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397

CAS  PubMed  Article  Google Scholar 

Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM et al (1999) 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma—phase I and II study. Acta Oncol 38:351–359

CAS  PubMed  Article  Google Scholar 

Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE et al (2004) Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104:642–648

CAS  PubMed  Article  Google Scholar 

Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12:3200–3208

CAS  PubMed  Article  Google Scholar 

Bruijnen STG, Chandrupatla DMSH, Giovanonni L, Neri D, Vugts DJ, Huisman MC et al (2019) F8-IL10: a new potential antirheumatic drug evaluated by a PET-guided translational approach. Mol Pharm 16:273–281

CAS  PubMed  Article  Google Scholar 

Islam MS, Kusakabe M, Horiguchi K, Iino S, Nakamura T, Iwanaga K et al (2014) PDGF and TGF-β promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice. Br J Pharmacol 171:375–388

CAS  PubMed  Article  Google Scholar 

Kawamura T, Yamamoto M, Suzuki K, Suzuki Y, Kamishima M, Sakata M et al (2019) Tenascin-C produced by intestinal myofibroblasts promotes colitis-associated cancer development through angiogenesis. Inflamm Bowel Dis 25:732–741

PubMed  Article  Google Scholar 

Rybak J-N, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2:291–298

CAS  PubMed  Article  Google Scholar 

Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D et al (2008) Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 123:2856–2864

CAS  PubMed  Article  Google Scholar 

Bootz F, Neri D (2016) Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discovery Today 21:180–189

CAS  PubMed  Article  Google Scholar 

Tolmachev V, Orlova A. (2020) Affibody molecules as targeting vectors for PET imaging. Cancers (Basel). ;12.

Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discovery 7:591–607

CAS  PubMed  Article  Google Scholar 

Zhang L, Bhatnagar S, Deschenes E, Thurber GM (2016) Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. Sci Rep 6:25424 (Nature Publishing Group)

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ongaro T, Gouyou B, Stringhini M, Corbellari R, Neri D, Villa A (2020) A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo. Oncotarget 11:3698–3711

PubMed  PubMed Central  Article  Google Scholar 

Zegers CML, Rekers NH, Quaden DHF, Lieuwes NG, Yaromina A, Germeraad WTV et al (2015) Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 21:1151–1160

CAS  PubMed  Article  Google Scholar 

Polakis P (2016) Antibody drug conjugates for cancer therapy. Esbenshade TA editor 68:3–19 (Pharmacological Reviews)

CAS  Google Scholar 

Diamantis N, Banerji U (2016) Antibody-drug conjugates—an emerging class of cancer treatment. British Journal of Cancer 114:362–7 (Nature Publishing Group)

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhang S, Langer R, Traverso G (2017) Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today 16:82–96

CAS  PubMed  PubMed Central  Article  Google Scholar 

Freise AC, Zettlitz KA, Salazar FB, Tavaré R, Tsai W-TK, Chatziioannou AF et al (2018) Immuno-PET in inflammatory bowel disease: imaging CD4-positive T cells in a murine model of colitis. Journal of Nuclear Medicine. 59:980–5

CAS  PubMed  PubMed Central  Article  Google Scholar 

Higashikawa K, Akada N, Yagi K, Watanabe K, Kamino S, Kanayama Y et al (2011) Exploration of target molecules for molecular imaging of inflammatory bowel disease. Biochem Biophys Res Commun 410:416–421

CAS  PubMed  Article  Google Scholar 

Bettenworth D, Reuter S, Hermann S, Weckesser M, Kerstiens L, Stratis A et al (2013) Translational 18F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. Journal of Nuclear Medicine 54:748–55 (Society of Nuclear Medicine)

CAS  PubMed  Article  Google Scholar 

Treglia G, Quartuccio N, Sadeghi R, Farchione A, Caldarella C, Bertagna F et al (2013) Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. Journal of Crohn’s and Colitis 7:345–354

PubMed  Article  Google Scholar 

Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proceedings of the National Academy of Sciences. 97:10701–5

CAS  Article  Google Scholar 

Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. :12.

Benatuil L, Perez JM, Belk J, Hsieh C-M (2010) An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel 23:155–159

CAS  PubMed  Article  Google Scholar 

Cilliers C, Nessler I, Christodolu N, Thurber GM (2017) Tracking antibody distribution with near-infrared fluorescent dyes: impact of dye structure and degree of labeling on plasma clearance. Mol Pharmaceutics American Chemical Society 14:1623–1633

CAS  Article  Google Scholar 

Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ et al (2012) A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Res 2:50